- BetterLife Pharma (BETR) is working on a key research publication on BETR-001, its proprietary 2-bromo-LSD
- BETR-001 is a non-hallucinogenic and non-controlled LSD derivative in development
- BETR-002 is based on honokiol, the active anxiolytic ingredient of magnolia bark
- BetterLife Pharma (BETR) is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders
- BetterLife Pharma (BETR) is unchanged today, trading at C$0.20 as of Sep 7, 2022, 1:13pm ET
BetterLife Pharma (BETR) is working on a key research publication on BETR-001, its proprietary 2-bromo-LSD.
The plan is to submit for review to a prestigious peer-reviewed journal by the end of September.
The emerging biotech company focuses on the development and commercialization of cutting-edge treatments for mental disorders.
The publication will present data from a preclinical in-vitro and in-vivo characterization of BETR-001 made in collaboration with three leading investigators in this field:
- Dr. Adam L. Halberstadt (University of California San Diego, USA)
- Dr. Argel Aguilar-Valles (Carleton University, Canada)
- Dr. John D. McCorvy (Medical College of Wisconsin, USA)
The publication will include a pharmacological profiling of BETR-001 against over 30 key neuroreceptors in parallel with its parent compound LSD, as well as in-vivo studies in mice, showing the non-hallucinogenic profile of BETR-001 as well its effective structural neuroplasticity and anti-depressant profile.
The research will provide insight into the mechanism for the non-hallucinogenic activity of BETR-001, as well as other key pharmacological differences between BETR-001 and LSD which could potentially translate into significant therapeutic benefits of BETR-001. Subject to the journal’s regulations, a pre-publication preprint will be posted as soon as possible for the public.
BETR-001 is a non-hallucinogenic and non-controlled LSD derivative in development. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent for composition and method of use covers treatment of depression, cluster headaches, post-traumatic stress disorder and other neuro-psychiatric and neurological disorders.
BETR-002 is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.
BetterLife Pharma (BETR) is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.
BetterLife Pharma (BETR) is unchanged today, trading at C$0.20 as of Sep 7, 2022, 1:13pm ET.